Previous studies with the bulbs of Cipura paludosa (Iridaceae) showed the presence of pyranonaphthoquinones, including eleutherine, isoeleutherine and eleutherol. The aim of this study was to evaluate the antifungal properties of these compounds. The activity was tested against the clinically relevant yeasts Candida albicans, C. tropicalis, Saccharomyces cerevisiae and Cryptococcus neoformans with the microbroth dilution method, following the guidelines of CLSI. Eleutherine, isoeleutherine and eleutherol all presented significant antifungal activity, especially the first two, the major components, with MIC values between 7.8 and 250 µg/mL. In conclusion, these results demonstrate that C. paludosa bulbs produce active principles with relevant antifungal potential, contributing, at least in part, to the antimicrobial effect evidenced for this plant and justifying its popular use against infections.
In the last years, considerable attention has been focused on natural products with antifungal properties, substantially increasing the number of antifungal drugs in this century [1] . Cipura paludosa Aubl. (Iridaceae), known as "batata-roxa", "alho-do-mato" and "cebolinha-do-campo", is widely found in the Amazon rainforest, in northern Brazil [2] , and has been traditionally used to treat various conditions such as inflammation, infections and pain. Previous studies have shown biological activities of C. paludosa, including antinociceptive, anti-inflammatory and neuroprotective effects [3] [4] [5] . Regarding its chemical composition, previous studies demonstrated the presence of eleutherine, isoeleutherine and hongkonin, as well as a new component, 11-hydroxyeleutherine, in the dichloromethane extract of the bulbs. The main components (eleutherine and isoeleutherine) exhibit pronounced activity in different in vivo models of inflammation and hypernociception [2] , and also promising antiproliferative activity. Screening of Brazilian medicinal plants had shown that the extracts of C. paludosa bulbs had promising antimicrobial action (unpublished results), and hence we have investigated the effects of eleutherine, isoeleutherine and eleutherol against some human pathogenic fungi.
The antifungal effect of the pyranonaphtoquinones eleutherine (1), isoeleutherine (2) and eleutherol (3) ( Figure 1 ) isolated from C. paludosa bulbs, was analyzed against four pathogenic fungi: Candida albicans, C. tropicalis, Saccharomyces cerevisiae and Cryptococcus neoformans. The selection of these species to evaluate the antifungal activity was associated with the clinical relevance of their infections and previous studies, which indicated MIC values (µg/mL) of 125, 250, 62.5 and 15.6 for the dichloromethane fraction of this plant against these fungi, respectively (Cechinel Filho, Personal communication).
Values of MIC and MFC of compounds 1-3 are shown in Table 1 . MIC values between 250 and 125 µg/mL were indicative of low activity, between 62.5 and 31.25 µg/mL moderate activity and ≤ 15.6 µg/mL, high activity. The percentage inhibition of fungal growth produced by the three compounds was calculated with the assistance of a microplate reader and the results are shown in Figure  2 . Table 1 demonstrate that 1 and 2 showed the best activity against all the tested species, especially against S. cerevisiae and C. neoformans. Analyzing the MIC 50 and MIC 80 , both compounds showed high activity against C. neoformans, and 1 also demonstrated high MIC 100 against this species demonstrating that 1 was more active than 2. They are epimeric isomers and possess a naphthoquinone 1,4-moiety with the methyl group (β-methyl for 1 and α-methyl for 2) as the only structural difference, Therefore, the higher activity of 1 seems to be related to the chirality at its pyran ring with the β-methyl group.
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The prevalence of systemic fungal infections has increased significantly in the last two decades, especially in immunocompromised patients and those with critical illnesses, having enormous impact on morbidity and mortality [6, 7] . The population also presents drug resistance due to the long use. There is, therefore, an urgent need for new antifungal chemical structures as alternatives to the existing ones [8] . The fungal pathogen C. neoformans is an encapsulated yeast that causes life-threatening infections, especially in immunocompromised patients. It is a very frequent cause of human disease and the number of cases of cryptococcosis worldwide is estimated at 1 million, with more than 600,000 deaths per year. So, new compounds with anticryptococcal activity are highly welcome [9] [10] [11] [12] . Among natural substances, studies with naphthoquinone derivatives have demonstrated their importance in vital biochemical processes and their several known biological activities, such as antitumor, antiviral, antibacterial, and especially antifungal [13] [14] [15] [16] [17] [18] .
Sassaki et al. [13] evaluated the antifungal activity of naphthoquinone derivatives and demonstrated MIC values of 8 -16 µg/mL against cultures of C. tropicalis, C. parapsilosis and C. neoformans. Rahmoun et al. [16] demonstrated that two naphthoquinone derivatives exhibited in vitro antibacterial activity with MICs ranging between 16 to 64 µg/mL.
To the best of our knowledge, this is the first report about the antifungal potential of these pyranonaphtoquinones against human pathogenic fungi, although preliminary studies have indicated that they are active against Pyricularia oryzae [19] and 1 exhibited antidermatophyte activity against Trichophyton mentagrophytes by agar diffusion assay [20] . (1), isoeleutherine (2) and eleutherol (3) (Figure 1) were isolated from C. paludosa bulbs according to previously described procedures [2] . 
Isolation of pyranonaphtoquinones: Eleutherine

Antifungal evaluation
Microorganisms and media: For the antifungal evaluation, standardized strains from the American Type Culture Collection (ATCC, Rockville, MD, USA) were used in a first instance of screening: C. albicans (ATCC 10231), C. tropicalis (CCC191), S. cerevisiae (ATCC 9763) and C. neoformans (ATCC 32264). Strains were grown on Sabouraud-chloramphenicol agar slants for 48 h at 30°C, maintained on slopes of Sabouraud-dextrose agar (SDA, Oxoid) and sub-cultured every 15 days to prevent pleomorphic transformations. Inocula of cell suspensions were obtained according to reported procedures and adjusted to 1-5 x 10 3 colony forming units (CFU)/mL [21] .
Minimum inhibitory concentration (MIC) determination:
Minimum inhibitory concentration (MIC) of each compound was determined by using broth microdilution techniques following the guidelines of the CLSI for yeasts [21] . MIC values were determined in RPMI-1640 (Sigma, St. Louis, MO, USA) buffered to pH 7.0 with MOPS (Sigma). Microtiter trays were incubated at 35°C for yeasts and hyalohyphomycetes and at 28°C for dermatophyte strains in a moist, dark chamber; MICs were recorded at 48 h for yeasts, and at a time according to the control fungal growth, for the rest of the fungi. The susceptibilities of the standard drug amphotericin B (Sigma-Aldrich, St. Louis, MO, USA) were defined as the lowest concentration of drug which resulted in total inhibition of fungal growth.
For the assay, compound stock solutions were two-fold diluted with RPMI-1640 from 250 to 0.24 µg/mL (final volume = 100 µL) and a final DMSO (Sigma) concentration <1%. A volume of 100 µL of inoculum suspension was added to each well with the exception of the sterility control where sterile water was added to the well instead. MIC was defined as the minimum inhibitory concentration of the compound, which resulted in total inhibition of the fungal growth.
MIC values were determined through three endpoints: MIC 100 , MIC 80 and MIC 50 (minimum concentration required to inhibit 100, 80 and 50% of fungal growth respectively). Minimum fungicide concentration (MFC), that is the concentration of compound that kills fungi rather than inhibits the fungal growth, was determined by plating duplicate 5 µL from each clear well of MIC determinations onto a 150 mm SDA plate. After 48 h at 37°C, MFCs were determined as the lowest concentration of each compound showing no growth in these plates.
Fungal growth inhibition percentage determination:
Broth microdilution techniques were performed in 96-well microplates according to the guidelines of the Clinical and Laboratory Standards Institute for yeasts (M27-A3) [21] . For the assay, compound test wells (CTWs) were prepared with stock solutions of each compound in DMSO (maximum concentration ≤ 1%), diluted with RPMI-1640 to final concentrations of 250-0.98 µg/mL. Inoculum suspension (100 µL) was added to each well (final volume in the well = 200 µL). A growth control well (GCW) (containing medium, inoculum, the same amount of DMSO used in CTW, but compound-free) and a sterility control well (SCW) (sample, medium and sterile water instead of inoculum) were included for each fungus tested. Microtiter trays were incubated in a moist, dark chamber at 30ºC for 48 h for C. albicans, C. tropicalis, S. cerevisiae and C. neoformans. Microplates were read in a VERSA Max microplate reader (Molecular Devices, Sunnyvale, CA, USA). Amphotericin B was used as positive control. Tests were performed in duplicate. Reduction of growth for each compound concentration was calculated as follows: % of inhibition = 100 -(OD 405 CTW -OD 405 SCW)/ (OD 405 GCW -OD 405 SCW). The mean ± SEM for individual tests and for 3 repeated tests were used for constructing the curves representing % inhibition vs concentration of each compound, SigmaPlot software was used.
